By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Where Your Profits Grow Sky High.

Apeiron tests effectiveness of APN01 on COVID-19 patients

COVID-19-Research © Medical University of Vienna

The Viennese company Apeiron Biologics AG is making use of a capital increase to further develop its COVID-19 and cell therapy pipeline. More specifically, it is examining the effectiveness of its drug candidate APN01 on patients who are seriously ill with COVID-19. This drug is designed to block the virus and protect the patients from respiratory failure. According to Apeiron, the financing is for future clinical studies as well as the availability of materials for treating COVID-19 patients. 200 ventilated patients are being treated with APNO1 within the context of phase II clinical studies which are already being conducted. The primary objective of the study is to investigate the clinical effectiveness of APN01 as well as the safety and tolerability of PNO1 in this patient population. The company believes an accelerated approval of the drug is conceivable if these goals are met.

APN01 is a recombinant form of ACE2 which blocks the binding of the virus on the basis of competitive binding on the viral spike protein and also has an anti-inflammatory effect. The product candidate was developed by the company founded by Josef Penninger especially for the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS).

Read more here about COVID-19 research in Austria.

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin



Meet us at events, seminars and trade shows - worldwide.

  • Investment Opportunities for Electronics Companies in Austria - Carinthia

    08.07.2020 / 2:30 pm IST, Online, Webinar

  • BIOMEDevice Boston 2020

    16. - 17.09.2020, Boston, USA

Austria Map

Find the perfect location for your company

Vienna’s unique location at the heart of Europe makes it an important centre and very popular with the global pharmaceutical and biotechnology industry. Vienna is where Eastern Europe meets Western Europe. Businesses located at this international hub benefit from well-established infrastructures and highly-qualified professionals. The significant growth in the Life Sciences sector in Vienna over the last few years is an indicator of the momentum in the industry.

ABF Pharmaceutical Services

ABF Pharmaceutical Services
More testimonials

news from the business location Austria

Austria registers more patents than ever before

Austrian companies and researchers registered 2.341 new patents at the European Patent Office (EPO) in 2019. Over the last five years the number of Austrian patent applications increased consistently.

Concerning Facebook and LinkedIn: Austrian companies in the social media jungle

A growing number of companies are relying on social media to inform customers, open up new target groups and identify suitable employees. Firms are increasingly investing in Facebook and other social media as each year passes, However, at the same time the continuous further development and establishment of networks are also leading to uncertainties about the right way of handling these platforms.

More news All blog posts